Cargando…
Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia
L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL). It hydrolyzes plasma asparagine into aspartate and NH(3), causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death. However, patient relapse often occurs due to devel...
Autores principales: | Kang, S M, Rosales, J L, Meier-Stephenson, V, Kim, S, Lee, K Y, Narendran, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658664/ https://www.ncbi.nlm.nih.gov/pubmed/28650467 http://dx.doi.org/10.1038/onc.2017.211 |
Ejemplares similares
-
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019) -
Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia
por: Underwood, Brynne, et al.
Publicado: (2020) -
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022) -
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017) -
Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen
por: Al Nabhani, Ibrahim, et al.
Publicado: (2022)